EPAD Terms and Conditions for accessing the V.IMI Dataset

On behalf of my research group accessing the EPAD V.IMI Dataset, I acknowledge that this data is for the advancement of scientific understanding of Alzheimer’s disease. As such I will make every effort to ensure that the analysis undertakes from the data will comply with the research question submitted as part of the access process and that this analysis will be published in peer reviewed scientific journals. I also acknowledge that in accessing this data I will not pass these data onto a third party. Should a third party seek access then they should be directed to the access system for the EPAD V.IMI Dataset. Please note that this does not apply to Participants accessing the EPAD V.IMI Dataset under their access rights set out in the Project Agreement for the European Prevention Of Alzheimer’s Dementia.

If you publish results that were generated using the EPAD data and/or samples then we do request acknowledgement of this and the grants that supported EPAD. The papers generated using EPAD data and/or samples must include the following elements:

- EPAD LCS is registered at www.clinicaltrials.gov Identifier: NCT02804789.
- Data used in preparation of this article were obtained from the EPAD LCS data set V.IMI, doi:10.34688/epadlcs_v.imi_20.10.30.
- This work used data and/or samples from the EPAD project which received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement n° 115736 and an Alzheimer’s Association Grant (SG 21-818099-EPAD).

Please refer to the EPAD Policy document for Publications on the EPAD website. Further details are provided in this document, which outlines the policies for publication and publication credits for those who use EPAD data and/or samples.